Adverse event profiles of adjuvant treatment with opicapone in Parkinson’s disease: A systematic review and meta-analysis

Background: Opicapone, a novel third-generation catechol-O-methyltransferase inhibitor, has demonstrated efficacy in Parkinson’s Disease (PD) patients with end-of-dose motor fluctuations. Objective: This study aimed to compare the short-term (<6 months) and long-term (≥6 months) tolerability of o...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Luwen, Qi, Xiaoyi, Wang, Xuan, He, Bing, Wang, Yu, Zhang, Wei, Yu, Zehui, Deng, Mingming, Liang, Sicheng, Lü, Muhan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9729693/
https://www.ncbi.nlm.nih.gov/pubmed/36506576
http://dx.doi.org/10.3389/fphar.2022.1042992

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9729693/
https://www.ncbi.nlm.nih.gov/pubmed/36506576
http://dx.doi.org/10.3389/fphar.2022.1042992

Ejemplares similares